These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - H.C. Wainwright has maintained its Buy rating and $240.00 price target on Krystal Biotech (NASDAQ:KRYS) as the company approaches its second-quarter 2025 financial results, expected in August. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.75, with analyst consensus strongly bullish at 1.36 (where 1 is Strong Buy).
The research firm noted that while Vyjuvek results have contributed to share volatility, it remains pleased with the launch trajectory of what it describes as a first-in-class therapy. The company’s impressive 93.2% gross profit margins and 247.5% year-over-year revenue growth support this positive outlook.
H.C. Wainwright highlighted the market’s focus on quarterly financial results for Vyjuvek, acknowledging Krystal Biotech’s transparency regarding various components of the product launch.
The firm’s maintained price target of $240.00 represents potential upside from current trading levels for the biotechnology company.
H.C. Wainwright’s reiterated Buy recommendation comes as investors await Krystal Biotech’s upcoming quarterly performance data for further insights into Vyjuvek’s commercial progress.
In other recent news, Krystal Biotech reported its first-quarter 2025 earnings, which fell short of analysts’ expectations. The company posted earnings per share (EPS) of $1.20, below the forecasted $1.46, and revenue of $88.18 million, missing the anticipated $99.12 million. Despite the earnings miss, Krystal Biotech saw a 95% year-over-year increase in net product revenue for its flagship treatment, VYJUVEK. H.C. Wainwright maintained a Buy rating for Krystal Biotech, with a price target of $240, highlighting the company’s robust cash reserves of $765.3 million. The firm noted that the revenue shortfall was anticipated due to seasonal insurance changes, but the impact was less pronounced than the previous year. Krystal Biotech is preparing for the launch of VYJUVEK in Germany in the third quarter of 2025, with further expansions planned in France and Japan. Additionally, the company is advancing its clinical pipeline, with several key data readouts expected by the end of the year. Meanwhile, Krystal Biotech’s ongoing clinical trials, including the KB707 study for lung cancer, have shown promising results, with an objective response rate of 36% in non-small cell lung cancer patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.